Engineered exosomes from different sources for cancer-targeted therapy DOI Creative Commons
Menghui Zhang,

Shengyun Hu,

Lin Liu

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: March 15, 2023

Exosome is a subgroup of extracellular vesicles, which has been serving as an efficient therapeutic tool for various diseases. Engineered exosomes are the sort modified with surface decoration and internal molecules. After appropriate modification, engineered able to deliver antitumor drugs tumor sites efficiently precisely fewer treatment-related adverse effects. However, there still exist many challenges clinical translation exosomes. For instance, what sources modification strategies could endow most activity poorly understood. Additionally, how choose appropriately in different therapies another unresolved problem. In this review, we summarized characteristics exosomes, especially spatial temporal properties. concluded recent advances cancer fields, including sources, isolation technologies, strategies, labeling imaging methods Furthermore, applications were summarized, such photodynamic therapy, gene immunotherapy. Consequently, above provides researchers community latest ideas on exosome new direction drug development, prospective accelerate cancer-targeted therapy.

Language: Английский

Management of glioblastoma: State of the art and future directions DOI Open Access
Aaron C. Tan, David M. Ashley,

Giselle Y. López

et al.

CA A Cancer Journal for Clinicians, Journal Year: 2020, Volume and Issue: 70(4), P. 299 - 312

Published: June 1, 2020

Abstract Glioblastoma is the most common malignant primary brain tumor. Overall, prognosis for patients with this disease poor, a median survival of <2 years. There slight predominance in males, and incidence increases age. The standard approach to therapy newly diagnosed setting includes surgery followed by concurrent radiotherapy temozolomide further adjuvant temozolomide. Tumor‐treating fields, delivering low‐intensity alternating electric can also be given concurrently At recurrence, there no care; however, surgery, radiotherapy, systemic chemotherapy or bevacizumab are all potential options, depending on patient's circumstances. Supportive palliative care remain important considerations throughout course multimodality management. recently revised classification glioblastoma based molecular profiling, notably isocitrate dehydrogenase ( IDH ) mutation status, result enhanced understanding underlying pathogenesis disease. clear need better therapeutic have been substantial efforts exploring immunotherapy precision oncology approaches. In contrast other solid tumors, biological factors, such as blood‐brain barrier unique tumor immune microenvironment, represent significant challenges development novel therapies. Innovative clinical trial designs biomarker‐enrichment strategies needed ultimately improve outcome glioblastoma.

Language: Английский

Citations

1530
The blood–brain barrier and blood–tumour barrier in brain tumours and metastases DOI
Costas D. Arvanitis, Gino B. Ferraro, Rakesh K. Jain

et al.

Nature reviews. Cancer, Journal Year: 2019, Volume and Issue: 20(1), P. 26 - 41

Published: Oct. 10, 2019

Language: Английский

Citations

1283
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma DOI Creative Commons
David A. Reardon, Alba A. Brandes, Antonio Omuro

et al.

JAMA Oncology, Journal Year: 2020, Volume and Issue: 6(7), P. 1003 - 1003

Published: May 21, 2020

Clinical outcomes for glioblastoma remain poor. Treatment with immune checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from a randomized phase 3 clinical trial evaluating programmed death-1 (PD-1) inhibitor therapy have not been reported.To determine whether single-agent PD-1 nivolumab improves survival patients recurrent compared bevacizumab.In this open-label, randomized, trial, 439 at first recurrence following standard radiation and temozolomide were enrolled, 369 randomized. Patients enrolled between September 2014 May 2015. The median follow-up was 9.5 months cutoff of January 20, 2017. study included 57 multicenter, multinational sites.Patients 1:1 to mg/kg or bevacizumab 10 every 2 weeks until confirmed disease progression, unacceptable toxic effects, death.The primary end point overall (OS).A total (n = 184) 185). MGMT promoter methylated 23.4% (43/184; nivolumab) 22.7% (42/185; bevacizumab), unmethylated 32.1% (59/184; 36.2% (67/185; reported remaining patients. At months, OS (mOS) comparable groups: nivolumab, 9.8 (95% CI, 8.2-11.8); bevacizumab, 10.0 9.0-11.8); HR, 1.04 0.83-1.30); P .76. 12-month 42% both groups. objective response rate higher (23.1%; 95% 16.7%-30.5%) vs (7.8%; 4.1%-13.3%). Grade 3/4 treatment-related adverse events (TRAEs) similar groups (nivolumab, 33/182 [18.1%]; 25/165 [15.2%]), no unexpected neurological TRAEs deaths due TRAEs.Although the met mOS patient population glioblastoma. safety profile consistent that other tumor types.ClinicalTrials.gov Identifier: NCT02017717.

Language: Английский

Citations

1083
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy DOI Creative Commons
Erik Henke, Rajender Nandigama, Süleyman Ergün

et al.

Frontiers in Molecular Biosciences, Journal Year: 2020, Volume and Issue: 6

Published: Jan. 30, 2020

Solid tumors are complex organ-like structures that consist not only of tumor cells but also vasculature, extracellular matrix (ECM), stromal and immune cells. Often this microenvironment (TME), comprises the larger part overall mass. Like other components TME ECM in solid differs significantly from normal organs. Intratumoral signaling, transport mechanisms, metabolisms, oxygenation, immunogenicity strongly affected if controlled by ECM. Exerting regulatory control, does influence malignancy growth its response towards therapy. Understanding particularities is necessary to develop approaches interfere with negative effect. In review, we will highlight current understanding physical, cellular molecular mechanisms which pathological affects efficiency radio-, chemo- immunotherapy. Finally, discuss various strategies target modify how they could be utilized improve

Language: Английский

Citations

846
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions DOI Open Access
Patrick Y. Wen, Michael Weller, Eudocia Q. Lee

et al.

Neuro-Oncology, Journal Year: 2020, Volume and Issue: 22(8), P. 1073 - 1113

Published: April 20, 2020

Abstract Glioblastomas are the most common form of malignant primary brain tumor and an important cause morbidity mortality. In recent years there have been advances in understanding molecular pathogenesis biology these tumors, but this has not translated into significantly improved outcomes for patients. consensus review from Society Neuro-Oncology (SNO) European Association (EANO), current management isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. addition, novel therapies such as targeted therapies, agents targeting DNA damage response metabolism, immunotherapies, viral reviewed, well challenges future directions research.

Language: Английский

Citations

832
Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells DOI Creative Commons
Florian Klemm, Roeltje R. Maas, Robert L. Bowman

et al.

Cell, Journal Year: 2020, Volume and Issue: 181(7), P. 1643 - 1660.e17

Published: May 28, 2020

Language: Английский

Citations

770
Mechanisms of immunotherapy resistance: lessons from glioblastoma DOI
Christopher M. Jackson, John Choi, Michael Lim

et al.

Nature Immunology, Journal Year: 2019, Volume and Issue: 20(9), P. 1100 - 1109

Published: July 29, 2019

Language: Английский

Citations

581
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma DOI
Kurt A. Schalper, María E. Rodríguez-Ruiz,

Ricardo Díez-Valle

et al.

Nature Medicine, Journal Year: 2019, Volume and Issue: 25(3), P. 470 - 476

Published: Feb. 11, 2019

Language: Английский

Citations

560
The Lymphatic Vasculature in the 21st Century: Novel Functional Roles in Homeostasis and Disease DOI Creative Commons
Guillermo Oliver, Jonathan Kipnis, Gwendalyn J. Randolph

et al.

Cell, Journal Year: 2020, Volume and Issue: 182(2), P. 270 - 296

Published: July 1, 2020

Language: Английский

Citations

515
Proteogenomic and metabolomic characterization of human glioblastoma DOI Creative Commons
Liang-Bo Wang, Alla Karpova, Marina Gritsenko

et al.

Cancer Cell, Journal Year: 2021, Volume and Issue: 39(4), P. 509 - 528.e20

Published: Feb. 11, 2021

Glioblastoma (GBM) is the most aggressive nervous system cancer. Understanding its molecular pathogenesis crucial to improving diagnosis and treatment. Integrated analysis of genomic, proteomic, post-translational modification metabolomic data on 99 treatment-naive GBMs provides insights GBM biology. We identify key phosphorylation events (e.g., phosphorylated PTPN11 PLCG1) as potential switches mediating oncogenic pathway activation, well targets for EGFR-, TP53-, RB1-altered tumors. Immune subtypes with distinct immune cell types are discovered using bulk omics methodologies, validated by snRNA-seq, correlated specific expression histone acetylation patterns. Histone H2B in classical-like immune-low driven largely BRDs, CREBBP, EP300. proteomic lipid distributions across global metabolic changes IDH-mutated This work highlights biological relationships that could contribute stratification patients more effective

Language: Английский

Citations

478